Detailed clinical and molecular evaluation of large cohorts of exceptional survivors provide an unprecedented opportunity to identify mechanisms underlying long term survival that can drive future therapeutic approaches and biomarker development. Exceptional survivors of high-grade serous ovarian cancer demonstrate concurrent disruption of homologous recombination DNA repair and retinoblastoma protein.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2zCyxLp
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου